Oncoclínicas, Brazil's leading oncology care provider, has reported its Q2 2026 results, revealing a severe impact from a medication supply crisis. The company's shares surged nearly 30% to $1.00 following the presentation, as investors focused on the return to positive adjusted EBITDA and operating cash flow. Gross revenue fell to R$ 1.23 billion in the quarter, down from R$ 1.66 billion in the prior-year period, due to medication shortages. However, a R$ 150 million private financing agreement helped partially normalize medication supply, setting the stage for gradual recovery.
Operational Performance
The company performed approximately 10,438 procedures during the quarter, down slightly from 10,585 in the first quarter but still above the 9,530 procedures in the prior-year period. The average ticket per procedure showed divergent trends, with a 32.6% quarter-over-quarter decline to R$ 114, but a 9.5% year-over-year increase.
Financial Metrics
Net revenue for the quarter came in at R$ 1.05 billion, reflecting the impact of higher provisions for loan losses. The company's adjusted EBITDA returned to positive territory at R$ 34.3 million after a negative R$ 49.2 million result in the first quarter. The adjusted EBITDA margin of 3.3% remained well below historical levels, but management emphasized that normalizing for the PCLD impact would yield a 9.5% margin.